Trial Profile
A Randomized, Open-Label, Phase 2 Study of Abemaciclib Plus Tamoxifen or Abemaciclib Alone, in Women With Previously Treated Hormone Receptor-Positive, HER2-Negative, Metastatic Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 14 Mar 2024
Price :
$35
*
At a glance
- Drugs Abemaciclib (Primary) ; Loperamide; Tamoxifen
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms nextMONARCH 1
- Sponsors Eli Lilly and Company
- 27 Oct 2023 Results deriving baseline and end-of-treatment plasma samples from patients in MONARCH 3 and nextMONARCH (monotherapy arms) to identify somatic genomic alterations, lished in the Clinical Cancer Research
- 11 Sep 2023 Planned End Date changed from 20 Sep 2023 to 30 Dec 2024.
- 05 Aug 2022 Planned End Date changed from 2 Aug 2023 to 20 Sep 2023.